GBP510 adjuvanted with Alum (RBD 10μg/dose) - Stage 1

Phase 2

Phase 2

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No catalyst events have been recorded for this drug yet.

Competitive Landscape

0 competitors in COVID-19 (Healthy Volunteers)

Drug Information

Target Indication

COVID-19 (Healthy Volunteers)

Clinical Trial

Last updated: 8/17/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Regulatory Approvals

EMAPending

Skycovion

Prevention of COVID-19 caused by SARS-CoV-2 in individuals 18 years of age and older

Drug Science

Mechanism of action & safety profile

Developer

BHIC

BioScience Health Innovations, Inc.

Related Pipeline

COVID-19

Covid19

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts